News & Analysis on Clinical Trial Services & Contract Research And Development
Drug research and development is facing a major problem with the sheer influx of data generated, which threatens to further slow down productivity, if its management and interpretation is not efficiently dealt with.
NJM/CLI has launched a system that simultaneously applies and verifies radiofrequency identification tags on bottles and other item level containers using a primary labeller, writes Phil Taylor.
French pharmaceutical company Pierre Fabre is to invest €30 million in its plant at Idron near Pau to bolster its contract manufacturing activities for injectable drugs.
Researchers in the US have developed a drug delivery technology that directs therapeutics directly to bone, raising the possibility of improved treatment for osteoporosis and other diseases affecting bone, including cancer, reports Phil Taylor.
DrugResearcher two-part special feature
In the first of a two-part interview, DrugResearcher.com took time out to talk to Dr. Tim Jaeger, director of business development at iAS interactive Systems, Germany. Speaking at the recent Drug Discovery Technology Europe conference in London,...
The prospect of using genomic analysis as a tool for studying trauma patients is a realistic prospect according to a new study, which says the tool can be used to predict whether or not a given patient will respond to a specific course of drug treatment.
Drug giants Novartis and Schering have announced a central review of study data failed to prove the results of its experimental cancer drug was "statistically significant" and was unable to exclude the possibility that the positive effect was accidental.
With the absence of any truly effective drug treatment for brain tumours, news of researchers working on innovative treatments for one of the deadliest tumour types raises the possibility of readdressing the current situation and brings hope for the...
As the US Food and Drug Administration continues its deliberations on generic biopharmaceuticals, the industry body representing generic drug manufacturers has said that the time has now come for the agency to make some hard decisions, reports Phil...